StreetInsider.com News Articles

Zymeworks names Suzanne Monahan as SVP Commercial for YUPELRI

Mon, 19 Oct 2026 06:00:14 -0400

Zymeworks Inc. (Nasdaq: ZYME) has appointed Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma, effective immediately, according to a company statement.

Monahan will report directly to Kenneth Galbraith, Chair and Chief Executive Officer, and will lead commercial strategy and execution for YUPELRI (revefenacin), a once-daily, nebulized long-acting muscarinic antagonist approved in the U.S. for the maintenance treatment of chronic obstructive pulmonary disease. The appointment follows Zymeworks' acquisition of Theravance Biopharma.

Monahan brings more than 20 years of commercial experience in the pharmaceutical and medical device industries. She most recently served as Senior Vice President at Pacira BioSciences, where

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

Mon, 19 Oct 2026 06:00:00 -0400

VANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that Suzanne Monahan has been appointed Senior Vice President, Commercial and General Manager, Theravance Biopharma, effective immediately. Reporting directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, Ms. Monahan will lead Zymeworks’ commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of chronic obstructive pulmonary

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

Mon, 19 Oct 2026 06:00:00 -0400

Form PRE 14A Zymeworks Inc. For: Dec 15

Fri, 16 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261016/27198123.html

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

Thu, 15 Oct 2026 06:00:00 -0400

Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026

VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its third quarter 2026 financial results after market close on November 9, 2026.

Consistent with its current practice, Zymeworks does not plan to host a conference call or webcast for its third quarter 2026 financial results. Management looks forward to engaging with the investment community at upcoming events.

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

Thu, 15 Oct 2026 06:00:00 -0400

Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026

Form 4 Zymeworks Inc. For: Oct 09 Filed by: Schayowitz Adam

Fri, 09 Oct 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20261009/27172478.html

Form 144 Zymeworks Inc. Filed by: Schayowitz Adam

Fri, 09 Oct 2026 11:17:00 -0400

si-local-file:///var/storage/secattach/20261009/27170333.html

Zymeworks (ZYME) PT Raised to $34 at Truist Securities

Wed, 07 Oct 2026 07:14:58 -0400

Truist Securities analyst Gregory Renza raised the price target on Zymeworks (NASDAQ: ZYME) to $34.00 (from $32.00) while maintaining a Buy rating.

TD Cowen Reinstates Zymeworks (ZYME) at Buy

Tue, 29 Sep 2026 09:34:02 -0400

TD Cowen analyst Yaron Werber reinstates coverage on Zymeworks (NASDAQ: ZYME) with a Buy rating and a price target of $34.00.

The analyst comments "ZYME closed the Theravance acquisition, underscoring a differentiated whole-company acquisition model that can access embedded commercial, royalty and R&D value. Mgmt expects mid-teens base-case IRR driven by Yupelri (should continue to grow in hospital channel), with multiple potential upside sources. FY26 guidance of $278-292M total revs and $114-128M adjusted EBITDA. Reinstating at Buy, PT $34."

For an analyst ratings summary and ratings history on Zymeworks click here. For more ratings news on Zymeworks click here.

Shares of

TD Cowen Reinstates Zymeworks (ZYME) at Buy

Tue, 29 Sep 2026 09:34:02 -0400

TD Cowen analyst Yaron Werber reinstates coverage on Zymeworks (NASDAQ: ZYME) with a Buy rating and a price target of $34.00.

For an analyst ratings summary and ratings history on Zymeworks click here. For more ratings news on Zymeworks click here.

Shares of

Zymeworks (ZYME) Reiterated at Market Outperform by Citizens as Theravance Biopharma Acquisition Closed

Tue, 29 Sep 2026 05:28:50 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $32.00 price target on Zymeworks (NASDAQ: ZYME).

The analyst commented, "We reiterate our Market Outperform rating for Zymeworks and a target price of $32, based on a discounted EPS and revenue multiple analysis. Yesterday, Zymeworks closed on the Theravance Biopharma acquisition bringing with it royalties, which by our estimates could peak at >$100MM in annual cash flow, a small commercial sales force, a potential $100MM milestone payment, as well as upside from several preclinical pipeline products. With zanidatamab royalties to contribute meaningfully in the coming years, ZW191 and ZW251 making steady

Zymeworks raises 2026 guidance after closing Theravance acquisition

Mon, 28 Sep 2026 06:01:19 -0400

Zymeworks Inc. (NASDAQ: ZYME) completed its acquisition of Theravance Biopharma and issued updated full-year 2026 financial guidance, according to a company press release.

The company now expects total 2026 revenue of between $278 million and $292 million, including collaboration revenue from YUPELRI® (revefenacin). Adjusted EBITDA for the full year is projected to be between $114 million and $128 million, excluding the impact of any future transactions.

Under the merger agreement, Theravance Biopharma shareholders received $17.00 in cash per share at closing. The acquisition was financed through a $350 million non-recourse note from OMERS Life Sciences, with 75% of YUPELRI profit-share cash flows

Zymeworks raises 2026 guidance after closing Theravance acquisition

Mon, 28 Sep 2026 06:01:19 -0400

Zymeworks Inc. (NASDAQ: ZYME) completed its acquisition of Theravance Biopharma and issued updated full-year 2026 financial guidance, according to a company press release.

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

Mon, 28 Sep 2026 06:00:00 -0400

Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assets
YUPELRI^® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRR
Zymeworks to retain existing commercial organization supporting YUPELRI hospital promotion
The Company expects total revenue, including collaboration revenue from YUPELRI, for 2026 to be between $278 million and $292 million and 2026 Adjusted EBITDA to be between $114 million and $128 million
Conference call with Zymeworks management today at 8:30 am Eastern Time (ET)

VANCOUVER,

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

Mon, 28 Sep 2026 06:00:00 -0400

Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assets
YUPELRI^® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRR
Zymeworks to retain existing commercial organization supporting YUPELRI hospital promotion
The Company expects total revenue, including collaboration revenue from YUPELRI, for 2026 to be between $278 million and $292 million and 2026 Adjusted EBITDA to be between $114 million and $128 million
Conference call with Zymeworks management today at 8:30 am Eastern Time (ET)

VANCOUVER,

Form 8-K Zymeworks Inc. For: Sep 23

Wed, 23 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260923/27096793.html

Zymeworks completes acquisition of Theravance Biopharma

Wed, 23 Sep 2026 16:01:12 -0400

Zymeworks Inc. (NASDAQ: ZYME) completed its acquisition of Theravance Biopharma on Sept. 23, 2026, making Theravance Biopharma a part of the Vancouver-based biotechnology company, according to a press release.

Zymeworks said the transaction is intended to advance its strategy of building a diversified revenue-generating biotechnology company that combines research and development with commercial and royalty-based cash flows.

The company plans to host a conference call on Sept. 28 at 8:30 a.m. Eastern Time to discuss the final transaction details of the acquisition.

Zymeworks' portfolio includes YUPELRI (revefenacin), Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody commercialized through partnerships with Jazz Pharmaceuticals and BeOne Medicines, and

Zymeworks Completes Acquisition of Theravance Biopharma

Wed, 23 Sep 2026 16:01:00 -0400

Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET)

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks’ strategy to build a diversified revenue-generating biotechnology company, combining innovative R&D with growing commercial and royalty-based cash flows.

Zymeworks will host

Zymeworks Completes Acquisition of Theravance Biopharma

Wed, 23 Sep 2026 16:01:00 -0400

Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET)

Zymeworks will host

Wolfe Research Starts Zymeworks (ZYME) at Outperform

Thu, 17 Sep 2026 05:03:15 -0400

Wolfe Research analyst Kalpit Patel initiates coverage on Zymeworks (NASDAQ: ZYME) with a Outperform rating.

For an analyst ratings summary and ratings history on Zymeworks click here. For more ratings news on Zymeworks click here.

Shares of Zymeworks closed at $26.24 yesterday.

Zymeworks (ZYME) PT Raised to $33 at JPMorgan

Thu, 03 Sep 2026 08:32:28 -0400

JPMorgan analyst Brian Cheng raised the price target on Zymeworks (NASDAQ: ZYME) to $33.00 (from $31.00) while maintaining a Overweight rating.

Zymeworks (ZYME) PT Raised to $55 at H.C. Wainwright

Wed, 26 Aug 2026 06:45:17 -0400

(Updated - August 26, 2026 6:45 AM EDT)

H.C. Wainwright analyst Andrew Berens raised the price target on Zymeworks (NASDAQ: ZYME) to $55.00 (from $51.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Zymeworks' partner, Jazz Pharmaceuticals (JAZZ; Under Review), announced that the FDA approved two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) regardless of PD-L1 expression: Ziihera plus Tevimbra (tislelizumab) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+). This approval is supported by the

Zymeworks (ZYME) PT Raised to $55 at H.C. Wainwright

Wed, 26 Aug 2026 06:45:17 -0400

(Updated - August 26, 2026 6:45 AM EDT)

H.C. Wainwright analyst Andrew Berens raised the price target on Zymeworks (NASDAQ: ZYME) to $55.00 (from $51.00) while maintaining a Buy rating.

Zymeworks (ZYME) Reiterated at Market Outperform by Citizens on FDA Approval for Zani

Wed, 26 Aug 2026 04:21:27 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $32.00 price target on Zymeworks (NASDAQ: ZYME).

The analyst commented, "We reiterate our Market Outperform rating on Zymeworks and price target of $32 based on a discounted EPS and revenue multiple analysis. Recently, Zymeworks reported 2Q26 earnings results, and yesterday announced the FDA approval of zanidatamab (zani) in 1L GEA. With zanidatamab royalties to contribute meaningfully in the coming years, ZW191 and ZW251 making steady progress in clinical development, a differentiated pan-RAS inhibitor ADC platform garnering considerable external interest, an ongoing share buy-back program and a solid cash position of $572.5MM